ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
<span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-size: small;"><span style="font-family: Times New Roman;"><p>Even if Chronic lymphocytic leukemia (CLL) often has an indolent behavio...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2010-05-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/6184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846098500362698752 |
|---|---|
| author | Patrizia Chiusolo Michela Tarnani Luca Laurenti Federica Sorà Simona Sica |
| author_facet | Patrizia Chiusolo Michela Tarnani Luca Laurenti Federica Sorà Simona Sica |
| author_sort | Patrizia Chiusolo |
| collection | DOAJ |
| description | <span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-size: small;"><span style="font-family: Times New Roman;"><p>Even if Chronic lymphocytic leukemia (CLL) often has an indolent behavior with good responsiveness to cytoreductive treatment, about 20% of the patients, so called "poor-risk" patients, show an aggressive course and die within a few years despite early intensive therapies. Criteria for poor-risk disease according to the European Bone Marrow Transplantation (EBMT) CLL Transplant Consensus are: purine analogue refractoriness, early relapse after purine analogue combination therapy, CLL with p53 lesion requiring treatment.</p><p>Allogeneic transplant has potential curative role in CLL, however burden with very high transplant related mortality (TRM) rates of 38-50%:</p><p>A major advance in reducing the short-term morbidity and mortality of allogeneic stem cell transplantation (SCT) has been the introduction of non-myeloablative or reduced intensity conditioning (RIC) regimens to allow engraftment of allogeneic stem cells. There is no doubt that the crucial therapeutic principle of allo-SCT in CLL is graft versus leukemia (GVL) activity.</p><p>The major complications of allogeneic SCT in CLL are: chronic graft-versus-host-disease (GVHD) affecting quality of life, high graft rejection and infection rates rates correlated with preexisting immunosuppression. Disease relapse remains the major cause of failure after RIC allo-HCT in CLL patients.</p><p>Sensitive minimal residual disease (MRD) quantification has strong prognostic impact after transplant. <strong></strong></p></span></span></span><p> </p> |
| format | Article |
| id | doaj-art-98eb8806e53341dd80a9efdf48fb36af |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2010-05-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-98eb8806e53341dd80a9efdf48fb36af2025-01-02T00:23:05ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062010-05-0122e2010026e2010026ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIAPatrizia ChiusoloMichela TarnaniLuca LaurentiFederica SoràSimona Sica<span style="mso-ansi-language: EN-US;" lang="EN-US"><span style="font-size: small;"><span style="font-family: Times New Roman;"><p>Even if Chronic lymphocytic leukemia (CLL) often has an indolent behavior with good responsiveness to cytoreductive treatment, about 20% of the patients, so called "poor-risk" patients, show an aggressive course and die within a few years despite early intensive therapies. Criteria for poor-risk disease according to the European Bone Marrow Transplantation (EBMT) CLL Transplant Consensus are: purine analogue refractoriness, early relapse after purine analogue combination therapy, CLL with p53 lesion requiring treatment.</p><p>Allogeneic transplant has potential curative role in CLL, however burden with very high transplant related mortality (TRM) rates of 38-50%:</p><p>A major advance in reducing the short-term morbidity and mortality of allogeneic stem cell transplantation (SCT) has been the introduction of non-myeloablative or reduced intensity conditioning (RIC) regimens to allow engraftment of allogeneic stem cells. There is no doubt that the crucial therapeutic principle of allo-SCT in CLL is graft versus leukemia (GVL) activity.</p><p>The major complications of allogeneic SCT in CLL are: chronic graft-versus-host-disease (GVHD) affecting quality of life, high graft rejection and infection rates rates correlated with preexisting immunosuppression. Disease relapse remains the major cause of failure after RIC allo-HCT in CLL patients.</p><p>Sensitive minimal residual disease (MRD) quantification has strong prognostic impact after transplant. <strong></strong></p></span></span></span><p> </p>http://www.mjhid.org/article/view/6184Chronic Lymphocytic LeukemiaFludarabineallogeneic transplantation |
| spellingShingle | Patrizia Chiusolo Michela Tarnani Luca Laurenti Federica Sorà Simona Sica ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA Mediterranean Journal of Hematology and Infectious Diseases Chronic Lymphocytic Leukemia Fludarabine allogeneic transplantation |
| title | ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_full | ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_fullStr | ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_full_unstemmed | ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_short | ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_sort | allogeneic transplantation for chronic lymphocytic leukemia |
| topic | Chronic Lymphocytic Leukemia Fludarabine allogeneic transplantation |
| url | http://www.mjhid.org/article/view/6184 |
| work_keys_str_mv | AT patriziachiusolo allogeneictransplantationforchroniclymphocyticleukemia AT michelatarnani allogeneictransplantationforchroniclymphocyticleukemia AT lucalaurenti allogeneictransplantationforchroniclymphocyticleukemia AT federicasora allogeneictransplantationforchroniclymphocyticleukemia AT simonasica allogeneictransplantationforchroniclymphocyticleukemia |